Skip to main content
OpenTrials
Completed

NCT Number: NCT01273272

Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers

The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild Alzheimer's dementia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–95 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Psychiatric University Hospital, Clinic for Geriatric Medicine

Zurich, 8032, Switzerland

About this study

Mild Alzheimer's dementia (AD) cases are with 15 millions worldwide the largest fraction of all AD cases. Most patients are cared for by their family at home. Neuropsychiatric symptoms are very common in AD, even as early as in mild AD: About 90% of all mild AD cases experience neuropsychiatric symptoms, most frequently depression, anxiety, and irritability. These symptoms are associated with greater morbidity, reduced quality of life for the patient, increased burden and depression for the caregiver, higher costs of care, and nursing home placement. Thus, interventions aimed at treating these symptoms could have a tremendous effect on pa-tients, caregivers, and society.

This study is a randomized, controlled trial (RCT) evaluating a comprehensive CBT-based, multi-component treatment programme consisting of eight modules (diagnosis and goal-setting; psycho-education; engagement in pleasant activities; cognitive restructuring; life review; training caregiver in behavior management techniques; interventions for the caregiver; couples counseling) and 20 sessions.

This trial aims at significantly reducing depressive and other neuropsychiatric symptoms in the AD patients, and secondary in reducing burden and depressive symptoms of the caregivers. Patients with AD alone or mixed AD and vascular dementia that are in the mild stage and suffer under any neuropsychiatric symptom will be included. The patients and their caregiver will be randomized to either the CBT-based intervention or to the control condition that receives treatment as usual (TAU).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients have to meet NINCDS-ADRDA criteria for probable or possible AD (McKhann et al., 1984). Mixed Alzheimer and Vascular dementia cases will also be included.
  • Only AD cases with a mild dementia severity will be included, determined by the Clinical Dementia Rating (CDR) scale (i.e. scores of 0.5 or 1, Morris, 1993) and by the Mini Mental State Examination (MMSE) (i.e. scores of 20 or more, Folstein, Folstein, & McHugh, 1975).
  • The patient must suffer under any non-cognitive symptom that motivates him to accept psy-chotherapeutic help.
  • A caregiver must be available to take part in most of the therapy sessions.

Exclusion criteria

  • concomitant alcohol or drug addiction and a history of a malignant disease, severe organ failure, metabolic or hematologic disorders, neurosurgery or neurological condition such as Parkinson's disease, epilepsy, postencephalitic and postconcussional syndrome

Treatment and study plan

Comprehensive, CBT-based, multi-component treatment

Behavioral

It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).

Other names: Psychosocial intervention

Treatment as Usual

Behavioral

Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.

Other names: Standard treatment

Primary outcomes

  1. Change from baseline in Geriatric Depression Scale (GDS)

    Time frame: Pre-treatment, posttreatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

Secondary outcomes

  1. Change from baseline in Neuropsychiatric Inventory (NPI)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  2. Change from baseline in Bayer-Activities of Daily Living (B-ADL)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  3. Change from baseline in Stress Coping Inventory (SCI)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  4. Change from baseline in Apathy Evaluation Scale (AES)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  5. Caregiver: Change from baseline in Center for Epidemiologic Studies Depression Scale (CES-D)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  6. Caregiver: Change from baseline in Trait scale of the State Trait Anxiety Inventory (STAI)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  7. Caregiver: Change from baseline in Anger-in and anger-out scales of the State Trait Anger Expression Inventory (STAXI)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  8. Caregiver: Change from baseline in Short-Form Health Survey (SF-12)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  9. Caregiver: Change from baseline in Zarit Burden Interview (ZBI)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  10. Caregiver: Change from baseline in Stress Coping Inventory (SCI)

    Time frame: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • Psychiatric University Hospital, Zurich

Registry information

Official study title

Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia: A Randomized Controlled Trial

Acronym: CBTAC

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Jan 10, 2011
Registry last updated
Nov 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.